Olgu Sunumu
PDF Mendeley EndNote BibTex Kaynak Göster

Alopecia areata after hepatitis C virus infection treatment: a case report

Yıl 2021, Cilt 3, Sayı 2, 185 - 187, 24.04.2021
https://doi.org/10.38053/acmj.886644

Öz

Interferon-free direct-acting antiviral (DAA) therapies in the chronic hepatitis C virus (HCV) infections have low side effects. Sofosbuvir / ribavirin (SOF / RBV) therapy combination is among in the currently approved treatment regimens. Aleopecia areata is a very rarely comlication of this treatment. A case of alopecia areata developed after SOF / RBV combination therapy in a patient with chronic hepatitis C infection is presented.

Kaynakça

  • Naggie S, Wyles DL. Hepatitis c. In. Bennett JE, Dolin R, Blaser MJ (eds). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Ninth ed. Philadelphia, United States: Elsevier, 2020; 154: 2040-73.
  • Welzel TM, Nelson DR, Morelli G, et al. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut 2017; 66: 1844-52.
  • Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001.
  • Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Smira G, Regep L. The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey 2006 - 2008. J Gastrointestin Liver Dis 2010; 19: 373-379.
  • Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77
  • Bal T, Çabalak M. Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3. Ann Med Res 2020; 27: 2067-71.
  • Bakulin IG, Konstantin Z, Vasil Y, et Al. Sofosbuvır Plus ribavirin for the treatment of russian patients with chronic hcv genotype 1 or 3 infection. Hepatology Internatıonal 2015: 9; 52-58.
  • Kurtaran B, Sarıgül F, Çabalak M. Efficacy and safety of direct-acting antivirals in chronic hepatitis C patients infected with genotype 2 and 3 in Turkey. AASLD-TASL Connect Regional Meeting, 15-16 March, 2019. İstanbul, Turkey, 59-60.
  • Örmeci N, Gülşen MT, Sezgin O, et al. Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. Turk J Gastroenterol 2020; 31: 148-55.
  • Taliani G, Biliotti E, Capanni M,    Tozzi A, Bresci S, Pimpinelli N. Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for chronic hepatitis C. J Chemother 2005; 17: 212-4.
  • Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142: 240-50.
  • Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 2006; 10: 1-183.
  • Maticic M, Poljak M, Lunder T, Rener-Sitar K, Stojanovic L. Lichen planus and other cutaneous manifestations in chronic hepatitis C: pre- and postinterferon-based treatment prevalence vary in a cohort of patients from low hepatitis C virus endemic area. J Eur Acad Dermatol Venereol 2008; 22: 779-88.
  • Podanyi B, Lengyel G, Harsing J, Becker K, Horvath A. Skin diseases associated with chronic hepatitis C. Orv Hetil 1998; 139: 2633-7.
  • Jadali Z, Mansouri P, Jadali F. These is no relationship between hepatitis C virus and alopecia areata. Eur J Dermatol 2006; 16: 94-5. 7. Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 2005; 38: 295-301.
  • Kartal ED, Alpat SN, Ozgunes I, Usluer G. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol 2007; 19: 817-20

Yıl 2021, Cilt 3, Sayı 2, 185 - 187, 24.04.2021
https://doi.org/10.38053/acmj.886644

Öz

Kaynakça

  • Naggie S, Wyles DL. Hepatitis c. In. Bennett JE, Dolin R, Blaser MJ (eds). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Ninth ed. Philadelphia, United States: Elsevier, 2020; 154: 2040-73.
  • Welzel TM, Nelson DR, Morelli G, et al. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut 2017; 66: 1844-52.
  • Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001.
  • Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Smira G, Regep L. The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey 2006 - 2008. J Gastrointestin Liver Dis 2010; 19: 373-379.
  • Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77
  • Bal T, Çabalak M. Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3. Ann Med Res 2020; 27: 2067-71.
  • Bakulin IG, Konstantin Z, Vasil Y, et Al. Sofosbuvır Plus ribavirin for the treatment of russian patients with chronic hcv genotype 1 or 3 infection. Hepatology Internatıonal 2015: 9; 52-58.
  • Kurtaran B, Sarıgül F, Çabalak M. Efficacy and safety of direct-acting antivirals in chronic hepatitis C patients infected with genotype 2 and 3 in Turkey. AASLD-TASL Connect Regional Meeting, 15-16 March, 2019. İstanbul, Turkey, 59-60.
  • Örmeci N, Gülşen MT, Sezgin O, et al. Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. Turk J Gastroenterol 2020; 31: 148-55.
  • Taliani G, Biliotti E, Capanni M,    Tozzi A, Bresci S, Pimpinelli N. Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for chronic hepatitis C. J Chemother 2005; 17: 212-4.
  • Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142: 240-50.
  • Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 2006; 10: 1-183.
  • Maticic M, Poljak M, Lunder T, Rener-Sitar K, Stojanovic L. Lichen planus and other cutaneous manifestations in chronic hepatitis C: pre- and postinterferon-based treatment prevalence vary in a cohort of patients from low hepatitis C virus endemic area. J Eur Acad Dermatol Venereol 2008; 22: 779-88.
  • Podanyi B, Lengyel G, Harsing J, Becker K, Horvath A. Skin diseases associated with chronic hepatitis C. Orv Hetil 1998; 139: 2633-7.
  • Jadali Z, Mansouri P, Jadali F. These is no relationship between hepatitis C virus and alopecia areata. Eur J Dermatol 2006; 16: 94-5. 7. Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 2005; 38: 295-301.
  • Kartal ED, Alpat SN, Ozgunes I, Usluer G. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol 2007; 19: 817-20

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Bilimleri ve Hizmetleri
Bölüm Case Report
Yazarlar

Esma EROĞLU (Sorumlu Yazar)
KONYA EĞİTİM VE ARAŞTIRMA HASTANESİ
0000-0002-0181-6023
Türkiye

Yayımlanma Tarihi 24 Nisan 2021
Yayınlandığı Sayı Yıl 2021, Cilt 3, Sayı 2

Kaynak Göster

Bibtex @olgu sunumu { acmj886644, journal = {Anatolian Current Medical Journal}, eissn = {2718-0115}, address = {MediHealth Academy Yayıncılık, Yukarı Sok, No: 6/1, Emniyet Mah., Yenimahalle, Ankara, Türkiye}, publisher = {MediHealth Academy Yayıncılık}, year = {2021}, volume = {3}, number = {2}, pages = {185 - 187}, doi = {10.38053/acmj.886644}, title = {Alopecia areata after hepatitis C virus infection treatment: a case report}, key = {cite}, author = {Eroğlu, Esma} }
APA Eroğlu, E. (2021). Alopecia areata after hepatitis C virus infection treatment: a case report . Anatolian Current Medical Journal , 3 (2) , 185-187 . DOI: 10.38053/acmj.886644
MLA Eroğlu, E. "Alopecia areata after hepatitis C virus infection treatment: a case report" . Anatolian Current Medical Journal 3 (2021 ): 185-187 <https://dergipark.org.tr/tr/pub/acmj/issue/61961/886644>
Chicago Eroğlu, E. "Alopecia areata after hepatitis C virus infection treatment: a case report". Anatolian Current Medical Journal 3 (2021 ): 185-187
RIS TY - JOUR T1 - Alopecia areata after hepatitis C virus infection treatment: a case report AU - Esma Eroğlu Y1 - 2021 PY - 2021 N1 - doi: 10.38053/acmj.886644 DO - 10.38053/acmj.886644 T2 - Anatolian Current Medical Journal JF - Journal JO - JOR SP - 185 EP - 187 VL - 3 IS - 2 SN - -2718-0115 M3 - doi: 10.38053/acmj.886644 UR - https://doi.org/10.38053/acmj.886644 Y2 - 2021 ER -
EndNote %0 Anatolian Current Medical Journal Alopecia areata after hepatitis C virus infection treatment: a case report %A Esma Eroğlu %T Alopecia areata after hepatitis C virus infection treatment: a case report %D 2021 %J Anatolian Current Medical Journal %P -2718-0115 %V 3 %N 2 %R doi: 10.38053/acmj.886644 %U 10.38053/acmj.886644
ISNAD Eroğlu, Esma . "Alopecia areata after hepatitis C virus infection treatment: a case report". Anatolian Current Medical Journal 3 / 2 (Nisan 2021): 185-187 . https://doi.org/10.38053/acmj.886644
AMA Eroğlu E. Alopecia areata after hepatitis C virus infection treatment: a case report. Anatolian Curr Med J / ACMJ / acmj. 2021; 3(2): 185-187.
Vancouver Eroğlu E. Alopecia areata after hepatitis C virus infection treatment: a case report. Anatolian Current Medical Journal. 2021; 3(2): 185-187.
IEEE E. Eroğlu , "Alopecia areata after hepatitis C virus infection treatment: a case report", Anatolian Current Medical Journal, c. 3, sayı. 2, ss. 185-187, Nis. 2021, doi:10.38053/acmj.886644

Interuniversity Board (UAK) Equivalency: 1b [Original research article published in journals scanned by international field indexes (included in indices other than the ones mentioned in 1a) - 10 POINTS].


The indexes of the journal's are;

18596


asos-index.png

f9ab67f.png

WorldCat_Logo_H_Color.png

      logo-large-explore.png

images?q=tbn:ANd9GcQgDnBwx0yUPRKuetgIurtELxYERFv20CPAUcPe4jYrrJiwXzac8rGXlzd57gl8iikb1Tk&usqp=CAU

index_copernicus.jpg


84039476_619085835534619_7808805634291269632_n.jpg





The platforms of the journal's are;

COPE.jpg

images?q=tbn:ANd9GcTbq2FM8NTdXECzlOUCeKQ1dvrISFL-LhxhC7zy1ZQeJk-GGKSx2XkWQvrsHxcfhtfHWxM&usqp=CAUicmje_1_orig.png

cc.logo.large.png

ncbi.png

ORCID_logo.pngimages?q=tbn:ANd9GcQlwX77nfpy3Bu9mpMBZa0miWT2sRt2zjAPJKg2V69ODTrjZM1nT1BbhWzTVPsTNKJMZzQ&usqp=CAU


images?q=tbn:ANd9GcTaWSousoprPWGwE-qxwxGH2y0ByZ_zdLMN-Oq93MsZpBVFOTfxi9uXV7tdr39qvyE-U0I&usqp=CAU






The
 
indexes/platforms of the journal are;

Crossref (DOI), Google Scholar, EuroPub, Directory of Research Journal İndexing (DRJI), Worldcat (OCLC), OpenAIRE, ASOS Index, ROAD, Turkiye Citation Index, ICI World of Journal's, Index Copernicus, Turk Medline, General Impact Factor. 


Ulakbim-TR Dizin, EBSCO, DOAJ, OAJI is under evaluation.

Journal articles are evaluated as "Double-Blind Peer Review"

Assoc Prof Dr Muhammed KIZILGÜL was qualified as an Associated Editor in ACMJ on 15/02/2020.

Assoc Prof Dr Kenan ÇADIRCI was qualified as an Associated Editor in ACMJ on 15/02/2020.

Assist Prof Dr İrfan KARAHAN was qualified as an Associated Editor in ACMJ on 15/02/2020 (he has been working as an editor since the first issue of the journal).

Assoc. Prof. Dr. Ercan YUVANÇ leaved, Assoc. Prof. Dr. Alpaslan TANOĞLU became the Editör in Chief in ACMJ on 13/05/2020.

The Directories (indexes) and Platforms we are included in are at the bottom of the page.